Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Two Survival Wins in NSCLC With Bispecific Seeking Worldwide Status

(MedPage Today) -- The investigational bispecific antibody ivonescimab significantly improved overall survival (OS) in PD-L1-positive advanced non-small cell lung cancer (NSCLC) compared with single-agent pembrolizumab (Keytruda), an updated analysis...

Two Survival Wins in NSCLC With Bispecific Seeking Worldwide Status

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Thursday 17 September →